Lantheus (NASDAQ:LNTH) Releases Earnings Results, Beats Expectations By $0.50 EPS

Lantheus (NASDAQ:LNTH) announced its earnings results on Thursday. The medical equipment provider reported $1.67 EPS for the quarter, beating the consensus estimate of $1.17 by $0.50, FiscalAI reports. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The business had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. During the same period in the prior year, the business posted $1.59 earnings per share. Lantheus’s revenue was up 4.0% compared to the same quarter last year. Lantheus updated its FY 2026 guidance to 5.000-5.250 EPS.

Here are the key takeaways from Lantheus’ conference call:

• Lantheus has refocused on PET radiodiagnostics, completing acquisitions of Neuraceq and OCTEVY and divesting its legacy SPECT business, which management says diversifies near‑term revenue and leaves the company with the broadest radiodiagnostic pipeline among peers.
• Management expects multiple near‑term regulatory milestones — PDUFA for the new PSMA F‑18 formulation (Mar 6), OCTEVY (Mar 29), MK‑6240 (Aug 13) and a mid‑year Hatch‑Waxman ruling for PNT2003 — and plans a regional PMF rollout of the new PSMA formulation in Q4 2026, with material commercial impact beginning in 2027.
• Reported Q4 revenue was $406.8M and FY‑2025 revenue $1.5416B; guidance for 2026 is $1.4–$1.45B in revenue and EPS of $5.00–$5.25, while management also expects PYLARIFY net revenue to decline ~8%–10% in 2026 as modest price erosion offsets volume.
• Cash generation weakened — Q4 operating cash flow fell to $90.2M (from $157.7M) and free cash flow to $81.4M — while the company incurred ~$21.7M of acquisition/integration/divestiture costs and other charges; it did repurchase $100M of shares and ended the quarter with ~$359.1M in cash.

Lantheus Stock Down 0.4%

LNTH traded down $0.29 during trading on Thursday, reaching $75.43. 2,191,128 shares of the stock traded hands, compared to its average volume of 762,766. The stock has a market cap of $5.00 billion, a price-to-earnings ratio of 31.69 and a beta of -0.08. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The stock’s 50-day simple moving average is $67.97 and its two-hundred day simple moving average is $60.01.

Lantheus News Roundup

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 beat — Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected, with improved margins and ROE, supporting near‑term earnings power. MarketBeat: Q4 results
• Positive Sentiment: Analyst upgrade — William Blair upgraded LNTH to “Outperform,” a vote of confidence that can support buying interest. Street Insider: William Blair upgrade
• Positive Sentiment: Price target increase — Citizens Jmp raised its price target to $78, which can provide a modest valuation floor for the shares. American Banking News: PT raise
• Neutral Sentiment: Earnings call / disclosure materials posted — Full earnings call transcript, slide deck and press release are available for investors to dig into segment details and management commentary. Seeking Alpha: Earnings call transcript
• Negative Sentiment: Cautious FY‑2026 guidance — Management set EPS guidance of $5.00–$5.25 (consensus ~5.16) and revenue guidance $1.4B–$1.5B (consensus ~$1.5B). The midpoint and lower end of the revenue range are slightly light versus Street expectations, creating near‑term uncertainty on growth trajectory. GlobeNewswire: Q4 results & guidance
• Negative Sentiment: Intraday selling on mixed setup — despite the beat and upgrades, investors pulled back on the guidance and booked profits after a big run from the stock in the prior year. WTOP: Earnings snapshot

Analyst Upgrades and Downgrades

A number of analysts have commented on LNTH shares. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday. Mizuho upped their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Citizens Jmp raised their price objective on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research note on Tuesday. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Finally, Truist Financial increased their target price on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $78.83.

Institutional Investors Weigh In On Lantheus

Large investors have recently made changes to their positions in the company. Alberta Investment Management Corp bought a new position in Lantheus during the fourth quarter valued at approximately $1,617,000. Vident Advisory LLC lifted its stake in shares of Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after purchasing an additional 230 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Lantheus by 31.1% in the fourth quarter. Mackenzie Financial Corp now owns 657,674 shares of the medical equipment provider’s stock worth $44,082,000 after purchasing an additional 156,081 shares in the last quarter. XTX Topco Ltd increased its position in Lantheus by 64.8% during the fourth quarter. XTX Topco Ltd now owns 18,440 shares of the medical equipment provider’s stock worth $1,227,000 after buying an additional 7,252 shares during the last quarter. Finally, Vestal Point Capital LP lifted its position in shares of Lantheus by 111.8% in the fourth quarter. Vestal Point Capital LP now owns 360,000 shares of the medical equipment provider’s stock worth $23,958,000 after buying an additional 190,000 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.